title: Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.
abstract: Targeted therapies have advanced the treatment options for cutaneous melanoma, but many patients will progress on drug. Patient-derived xenografts (PDX) can be used to recapitulate therapy-resistant tumors. Furthermore, PDX modeling can be utilized in combination with targeted sequencing and phosphoproteomic platforms, providing preclinical basis for second-line targeted inhibitor strategies. See related article by Krepler et al., p. 1592.
authors: Department of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
authors: Edward J
authors: EJ
authors: Hartsough
authors: Department of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. Andrew.Aplin@Jefferson.edu.
authors: Andrew E
authors: AE
authors: Aplin
mesh_terms: D000818:Animals; D064593:Heterografts; D006801:Humans; D008545:Melanoma; D051379:Mice; D057285:Precision Medicine; D014183:Transplantation, Heterologous; D023041:Xenograft Model Antitumor Assays